Statement Of Changes In Equity [Abstract]

Medistim - Filing #2546555

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity
397 941 NOK
307 380 NOK
19 394 NOK
41 852 NOK
4 585 NOK
13,000 NOK
326 774 NOK
71 167 NOK
24 743 NOK
367 691 NOK
16 797 NOK
41 852 NOK
285 736 NOK
21,000 NOK
4 585 NOK
65 158 NOK
302 533 NOK
18 742 NOK
26,000 NOK
240 160 NOK
6 138 NOK
13 344 NOK
306 052 NOK
246 298 NOK
59 754 NOK
41 852 NOK
4 585 NOK
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)
103 823 NOK
113 973 NOK
Comprehensive income
- NOK
106 420 NOK
2 597 NOK
103 823 NOK
- NOK
- NOK
- NOK
106 420 NOK
- NOK
- NOK
- NOK
10 659 NOK
124 632 NOK
113 973 NOK
124 632 NOK
- NOK
- NOK
- NOK
Dividends recognised as distributions to owners
- NOK
82 180 NOK
- NOK
82 180 NOK
- NOK
- NOK
- NOK
82 180 NOK
- NOK
- NOK
68 396 NOK
68 396 NOK
68 396 NOK
Increase (decrease) through share-based payment transactions, equity
8,000 NOK
6 009 NOK
- NOK
- NOK
- NOK
- NOK
6 009 NOK
- NOK
6 001 NOK
- NOK
6,000 NOK
- NOK
5 404 NOK
- NOK
- NOK
5 404 NOK
- NOK
5 398 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.